2007
DOI: 10.1016/j.jaci.2006.12.631
|View full text |Cite
|
Sign up to set email alerts
|

The First Placebo-Controlled Trial in Cryopyrin-Associated Periodic Syndromes (CAPS): IL-1 Trap (rilonacept) Markedly Reduces Clinical and Laboratory Abnormalities in Patients with Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles